Pilatus Biosciences Presents Preclinical PLT012 Data at SITC 2026
The company presented preclinical data on PLT012's potential to overcome immunotherapy resistance in liver cancer. Research identifies CD36-mediated lipid metabolism as a driver of acquired resistance to PD-1 immunotherapy.